Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection?
M. Goldman et al., Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection?, ANTIM AG CH, 44(6), 2000, pp. 1585-1587
The effects of prolonged itraconazole exposure on the susceptibility of Can
dida albicans isolates to itraconazole and fluconazole have not been well c
haracterized. A recent placebo-controlled study of long-term itraconazole a
ntifungal prophylaxis in persons with advanced human immunodeficiency virus
infection afforded the opportunity to address this question, Mucosal Candi
da sp, isolates were obtained from subjects who developed oropharyngeal or
esophageal candidiasis, and in vitro susceptibilities of the last isolate o
btained at removal from the study as a prophylaxis failure were compared in
itraconazole and placebo recipients, More subjects in the placebo group (7
4 of 146 [51%]) than in the itraconazole group (51 of 149 [34%]) developed
mucosal candidiasis (P = 0.001). A total of 112 isolates were recovered fro
m 56 of the 74 (76%) subjects with mucosal candidiasis assigned to the plac
ebo group, compared to 97 isolates from 45 of the 51 (88%) subjects in the
itraconazole group. C. albicans accounted for 98% of isolates in the placeb
o group and 89% of isolates in the itraconazole group. The itraconazole MIC
at which 50% of the isolates tested were inhibited (MIC50) for last-episod
e isolates from the itraconazole group was 0.125 mu g/ml compared to 0.015
mu g/ml for the placebo group subjects, P = 0.0001. The MIC50 of fluconazol
e for the last isolates from the itraconazole group was 1.5 mu g/ml compare
d to 0.5 mu g/ml for the placebo subjects (P = 0.005), A lower proportion o
f isolates recovered from subjects on itraconazole therapy were classified
as susceptible to itraconazole (63%) compared to isolates from the placebo
group (96%) (P = 0.001). Similarly, a lower proportion of C, albicans isola
tes from subjects on itraconazole therapy were susceptible to fluconazole (
78%) compared to isolates from the placebo group (96%) (P = 0.01), Also, th
e proportion of isolates that were not fully susceptible to itraconazole or
fluconazole was greater in patients assigned to the itraconazole group tha
n the placebo group (itraconazole susceptibility, 37 and 4%, respectively (
P = 0.001); fluconazole susceptibility, 23 and 4%, respectively (P = 0.01),
In conclusion, long-term itraconazole prophylaxis in patients with AIDS is
associated with reduction in susceptibility to itraconazole and cross-resi
stance to fluconazole.